Andrew P Byrnes

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Challenges and future prospects in gene therapy
    Andrew P Byrnes
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    IDrugs 8:993-6. 2005
  2. doi request reprint Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Food and Drug Administration Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA
    Hum Gene Ther 19:547-54. 2008
  3. ncbi request reprint Rapid Kupffer cell death after intravenous injection of adenovirus vectors
    Elanchezhiyan Manickan
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Mol Ther 13:108-17. 2006
  4. pmc Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor
    Zhili Xu
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Mol Ther 18:609-16. 2010
  5. pmc Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement
    Zhili Xu
    Division of Cellular and Gene Therapies, FDA CBER, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 82:11705-13. 2008
  6. doi request reprint Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement
    Zhili Xu
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Nat Med 19:452-7. 2013
  7. ncbi request reprint A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Food and Drug Administration, Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA
    J Virol Methods 147:54-60. 2008
  8. pmc Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo
    Jie Tian
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 83:5648-58. 2009
  9. ncbi request reprint Quality prediction of cell substrate using gene expression profiling
    Jing Han
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29B, Room 2NN20, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Genomics 87:552-9. 2006
  10. ncbi request reprint Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Mol Ther 9:932-41. 2004

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Challenges and future prospects in gene therapy
    Andrew P Byrnes
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    IDrugs 8:993-6. 2005
    ....
  2. doi request reprint Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Food and Drug Administration Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA
    Hum Gene Ther 19:547-54. 2008
    ..We conclude that Ad vectors kill KCs at a postbinding step and that this cell death can be mitigated if downstream events in viral entry are blocked...
  3. ncbi request reprint Rapid Kupffer cell death after intravenous injection of adenovirus vectors
    Elanchezhiyan Manickan
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Mol Ther 13:108-17. 2006
    ..Together these results show that an intravenous injection of adenovirus vector causes synchronous and surprisingly rapid Kupffer cell death...
  4. pmc Induction of shock after intravenous injection of adenovirus vectors: a critical role for platelet-activating factor
    Zhili Xu
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Mol Ther 18:609-16. 2010
    ..The identification of this novel pathway suggests strategies to improve the safety of systemic gene therapy with Ad vectors...
  5. pmc Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement
    Zhili Xu
    Division of Cellular and Gene Therapies, FDA CBER, 8800 Rockville Pike, Bethesda, MD 20892, USA
    J Virol 82:11705-13. 2008
    ....
  6. doi request reprint Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement
    Zhili Xu
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA
    Nat Med 19:452-7. 2013
    ..We conclude that Ad5 recruits FX as a defense against complement and that the sensitivity of Ad5 to inactivation by complement must be taken into account when designing vectors for systemic gene therapy...
  7. ncbi request reprint A quantitative assay for measuring clearance of adenovirus vectors by Kupffer cells
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Food and Drug Administration, Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA
    J Virol Methods 147:54-60. 2008
    ..As an example of the utility of this method, it was found that pre-injecting mice with polyinosinic acid reduces accumulation of Ad in Kupffer cells by approximately 90%...
  8. pmc Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo
    Jie Tian
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 83:5648-58. 2009
    ..In vitro studies are poorly predictive of in vivo mechanisms because Ad virions activate complement through indirect mechanisms in vivo...
  9. ncbi request reprint Quality prediction of cell substrate using gene expression profiling
    Jing Han
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Building 29B, Room 2NN20, 29 Lincoln Drive, Bethesda, MD 20892, USA
    Genomics 87:552-9. 2006
    ..Our results demonstrate that gene expression profiling can assess the quality of cell substrates prior to large-scale production of a biological product...
  10. ncbi request reprint Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats
    Jeffrey S Smith
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Mol Ther 9:932-41. 2004
    ....
  11. doi request reprint Th1 cytokines are upregulated by adenoviral vectors in the brains of primed mice
    Marco B Lee
    University of Oxford, Department of Physiology, Anatomy and Genetics, Oxford, UK
    Neuroreport 19:1187-92. 2008
    ..This knowledge of the molecular regulation of the immune response provides insight into targets, which could be manipulated to reduce inflammation in immunologically primed animals...